Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$41.81 USD

41.81
155,763

+0.01 (0.02%)

Updated Jul 24, 2024 04:00 PM ET

After-Market: $41.81 0.00 (0.00%) 5:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Here's Why You Should Hold HealthEquity (HQY) Stock for Now

HealthEquity's (HQY) fiscal third-quarter results hold promise while competition is stiff.

Medtronic's Mazor Buyout Creates a New Spine Surgery Major

With the acquisition of Mazor Robotics, Medtronic (MDT) expects to offer a fully-integrated procedural solution for surgical planning, execution and confirmation.

Baxter Stock up on Launch of Disposable Curved Applicator

Baxter's (BAX) wide array of surgical products see lucrative market prospects.

Surmodics Sees Hammer Chart Pattern: Time to Buy?

Surmodics has been struggling lately, but the selling pressure may be coming to an end soon.

GNC Holdings Global Business Strong, Same Store Sales Weak

GNC Holdings' (GNC) domestic franchise revenues worsen due to soft retail same store sales and fewer franchise stores.

Here's Why You Should Hold Cooper Companies (COO) Stock Now

Cooper Companies' (COO) strong CVI segment favors the stock while a soft Fertility unit raises concern.

Here's Why You Should Buy Haemonetics (HAE) Stock Right Now

Haemonetics (HAE) continues to witness strong growth in Plasma franchise.

Cerner's (CERN) Millennium Picked by Mid-Valley Hospital

Cerner's (CERN) EHR platforms have seen a series of developments in recent times.

Are ABMD & DXCM Neck and Neck? Let's Take a Closer Look

DexCom (DXCM) scores higher than Abiomed (ABMD) when it comes to current-year revenue projections and fundamentals.

Hologic's (HOLX) New Offering to Revitalize Cynosure Division

The latest launch along with certain new developments is expected to boost top-line contribution from Hologic's (HOLX) Cynosure division in the near term.

Bruker Profits from NANO & CALID, New Buyout Holds Promise

Bruker (BRKR) looks to gain from high demand for ADVANCE X-ray and nano-analysis products. The CALID Group also raises hope with high-single digit robust year-to-date revenues.

Thermo Fisher (TMO) Rides on New Buyouts and APAC Strength

We are upbeat about Thermo Fisher's (TMO) recent buyout of Advanced Bioprocessing business, which will add complementary cell culture products to the company's bioproduction suit.

Varian Medical's Eclipse Picked by Paul Scherrer Institute

Varian Medical's (VAR) latest developments fortify its foothold in the global cancer therapeutics market.

Here's Why You Should Hold Baxter International (BAX) Now

Baxter's (BAX) recent string of developments boost the stock while segmental softness is a concern.

Edwards Lifesciences Advances in AI With Bay Labs Tie-Up

Through the tie-up, Edwards Lifesciences (EW) aims at improving detection of heart diseases and enhancing quality by using Bay Labs' ability to apply AI to cardiovascular imaging.

CVS Health Aetna Synergy Impressive, PBM Selling Season Solid

CVS Health (CVS) estimates a $750-million earning from near-term synergies with low- to mid-single digit addition in the second year after the closure of Aetna transaction.

STERIS Rides on Favorable Industry Trends, Rivalry a Concern

STERIS (STE) is currently displaying strong top-line growth on encouraging market trends along with a new product and service portfolio.

NuVasive's Monolith Corpectomy System Ok'd for Expanded Use

NuVasive's (NUVA) latest FDA 510 (k) clearance receipt is expected to augment customer base and market reach.

Hologic Unveils Omni Hysteroscope, Boosts GYN Surgical Arm

Hologic (HOLX) highlights that a direct visualization of the uterine cavity in women with abnormal uterine bleeding will set a benchmark for the medical test.

Hill-Rom Adds New Capabilities to Centrella Smart+ Beds

Hill-Rom (HRC) stays focused on expansion through product development. The latest move is expected to boost the top-line results of the company.

Varian Medical ProBeam-Equipped Emory Center Opens in Georgia

Varian Medical's (VAR) flagship ProBeam system has lucrative prospects.

Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now

Myriad Genetics (MYGN) see strong testing volumes from new products.

Baxter & EFCNI Collaborate to Improve Care for Preterm Born

Baxter's (BAX) latest move is likely to increase the use of Baxter's Numeta G13E triple-chamber PN product.

Here's Why You Should Invest in athenahealth (ATHN) Now

A strong guidance and focus on big data-based health records system make athenahealth (ATHN) a solid investment pick.

Illumina (ILMN) Takes Part in NIH Program With Genotype Launch

The new Infinium Global Diversity Array of Illumina (ILMN) will process up to 1 million cost-free samples to the three genome centers.